Financhill
Back

Relay Therapeutics Quote, Financials, Valuation and Earnings

Relay Therapeutics Price Quote

$7.50

Relay Therapeutics Key Stats

Sell
33
Relay Therapeutics (RLAY) is a Sell

Day range:
$7.32 - $7.86
52-week range:
$5.70 - $12.14
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
27.10
P/B ratio:
1.47%

Volume:
1.7M
Avg. volume:
2.5M
1-year change:
-14.87%
Market cap:
$1B
Revenue:
$25.5M
EPS:
$-2.52

How Much Does Relay Therapeutics Make?

Data Unavailable

Is Relay Therapeutics Growing As A Company?

Data Unavailable

Relay Therapeutics Stock Price Performance

What Is Relay Therapeutics 52-Week High & Low?

Relay Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Relay Therapeutics?

Is Relay Therapeutics Cash Flow Positive?

  • What Is RLAY Cash Flow From Operations?
    Cash flow from operations (TTM) is -$280.7M
  • What Is Relay Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $81.8M
  • What Is Relay Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $187.1M

Relay Therapeutics Return On Invested Capital

Data Unavailable

Relay Therapeutics Earnings Date & Stock Price

Relay Therapeutics Competitors

  • Who Are Relay Therapeutics's Competitors?
    Below is a list of companies who compete with Relay Therapeutics or are related in some way:
    • Beam Therapeutics Inc (BEAM)
    • Celldex Therapeutics Inc (CLDX)
    • Caribou Biosciences Inc (CRBU)
    • Summit Therapeutics Inc (SMMT)
    • Terns Pharmaceuticals Inc (TERN)

Relay Therapeutics Dividend Yield

Relay Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 5.64%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 7
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 22.30
Upside from Last Price: 197.33%

Major Shareholders

  • How many RLAY shares are owned by institutional investors?
    169.2M RLAY shares are owned by institutional investors
  • How many RLAY shares are owned by insiders?
    3.7M RLAY shares are owned by insiders